Xianmin Meng

Xianmin Meng

Auto-generated profile, based on publicly available information

Xianmin Meng

Department of Pharmacy Shanghai Public Health Clinical Center Fudan University Shanghai China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Emerging Microbes & Infections
Verified
Journal Article
Open access
XMXianmin Meng
Xianmin Meng
PWPeipei Wang
Peipei Wang
YXYanqing Xiong
Yanqing Xiong
YWYijun Wu
Yijun Wu
XLXiaoyan Lin
Xiaoyan Lin
HLHongzhou Lu
Hongzhou Lu
MW33 is a fully humanized IgG1κ monoclonal neutralizing antibody, and may be used for the prevention and treatment of coronavirus disease 2019 (COVID-19). We conducted a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of MW33. Healthy adults aged 18–45 years were sequentially enrolled into the 4, 10, 20, 40, and 60 mg/kg dose groups and infused with MW33 over 60 ± 15 min and followed for 85 days. All 42 enrolled participants completed the MW33 infusion, and 40 participants completed the 85-day follow-up period. 34 participants received a single infusion of 4 (n = 2), 10 (n = 8), 20 (n = 8), 40 (n = 8), and 60 mg/kg (n = 8) of MW33. 27 subjects in the test groups experienced 78 adverse events (AEs) post-dose, with an incidence of 79.4% (27/34). The most common AEs included abnormal laboratory test results, vascular and lymphatic disorders, and infectious diseases. The severity of AEs was mainly Grade 1 (92 AEs), and three Grade 2 and one Grade 4. The main PK parameters, maximum concentration (Cmax), and area under the concentration-time curve (AUC0–t, and AUC0–∞) in 34 subjects showed a linear kinetic relationship in the range of 10–60 mg/kg. The plasma half-life was approximately 25 days. The positive rates of serum ADAs and antibody titres were low with no evidence of an impact on safety or PK. In conclusion, MW33 was well-tolerated, demonstrated linear PK, with a lower positive rate of serum ADAs and antibody titres in healthy subjects. Trial registration: ClinicalTrials.gov identifier: NCT04427501. Trial registration: ClinicalTrials.gov identifier: NCT04533048. Trial registration: ClinicalTrials.gov identifier: NCT04627584.

2 January 2023 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
GMGuangyan Mu
Guangyan Mu
QXQiufen Xie
Qiufen Xie
ZLZhiyan Liu
Zhiyan Liu
HZHanxu Zhang
Hanxu Zhang
XMXianmin Meng
Xianmin Meng
YCYimin Cui
Yimin Cui
Apixaban is a superior direct oral anticoagulant that exhibits interindividual variability in concentration and response in the real world. The present study aimed to identify the genetic biomarker...

4 May 2022 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
HWHaini Wen
Haini Wen
LYLin Yin
Lin Yin
JWJiangrong Wang
Jiangrong Wang
TSTao Sun
Tao Sun
FXFeng Xu
Feng Xu
LZLijun Zhang
Lijun Zhang
Lamivudine is a first-line medication used for human immunodeficiency virus (HIV) treatment. To date, the population pharmacokinetics of lamivudine in Chinese HIV-infected adults have not been assessed. This study aimed to develop a population pharmacokinetic model for oral lamivudine in Chinese HIV-infected adults and to determine the optimal lamivudine dosage regimens. A total of 1113 samples, from 828 Chinese HIV-infected patients treated with lamivudine 300 mg every 24 hours, were pooled from two open-label, prospective clinical trials. A population pharmacokinetics analysis was performed using a nonlinear mixed-effects modeling method. A Monte Carlo simulation was conducted to optimize lamivudine dosing. A two-compartment model adequately described the population pharmacokinetics of lamivudine. The typical population estimate for apparent clearance was 28.3 L/h. Creatinine clearance was identified as a significant factor influencing apparent clearance. According to the Monte Carlo simulation, patients with creatinine clearance between 50 and 70 mL/min should receive lamivudine 200 mg every 24 h or 300 mg every 36 h, to achieve optimal lamivudine exposure. No obvious ethnic differences were observed in lamivudine pharmacokinetics between Chinese and Caucasian populations. Additionally, a model-informed dosage regimen is recommended for patients with impaired renal function.

22 January 2025 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
LZLi Zhang
Li Zhang
JCJun Chen
Jun Chen
XLXiao‐Yan Lin
Xiao‐Yan Lin
YLYan Lu
Yan Lu
YWYan Wu
Yan Wu
XMXian‐Min Meng
Xian‐Min Meng

13 June 2020
Verified
Book Chapter
Closed access
PDF file
XMXianmin Meng
Xianmin Meng
QZQian Zhang
Qian Zhang
PDPing Dong
Ping Dong